Pub Date : 2024-03-20DOI: 10.58838/2075-1230-2024-102-1-26-33
A. Budnevskiy, S. N. Avdeev, E. S. Ovsyannikov, N. Alekseeva, V. V. Shishkina, I. Savushkina, I. M. Perveeva, V. R. Drobysheva
The objective: to determine the involvement of lung mast cell carboxypeptidase A3 (SPA3) in the pathogenesis of COVID-19. Subjects and Methods. Samples of autopsy specimens from the lungs of patients who died of severe COVID-19 and patients who died of external causes were examined. On day 2 after the patient's death, the autopsy was performed and autopsy specimens were collected. Histological samples were prepared to analyze the degranulation activity of CPA3-positive mast cells (MCs). Correlations between protease profile and clinical and laboratory parameters were analyzed.Results. In the patients died of COVID-19, the total numbers of CPA3-positive MCs, CPA3-positive MCs with signs of degranulation, and coadjacent CPA3-positive MCs (two CPA3-positive MCs sharing a common cytoplasm) were statistically significantly higher versus the patients from Control Group. Positive correlations were established between the total number of CPA3-positive MCs and CPA3-positive MCs with signs of degranulation with blood hemoglobin level (r = 0.491; p = 0.008; r = 0.521; p = 0.004), between the total number of CPA3-positive MCs degranulating CPA3-positive MCs and adjacent CPA3-positive MCs with total blood protein (r = 0.431, p = 0.020; r = 0.449, p = 0.015; r = 0.456, p = 0.013), and between CPA3-positive MCs with signs of degranulation and total number of CPA3-positive MCs with aPTT level (r = 0.428; p = 0.021; r = 0.374; p = 0.045). Negative correlations were established between the total number of CPA3-positive MCs and the level of INR (r = 0.812; p = 0.050), separately lying CPA3-positive MCs with the number of monocytes (r = 0.384; p = 0.044), jointly adjacent CPA3-positive Mcs with blood eosinophils (r = 0.420, p = 0.023).
{"title":"Certain Aspects of Mast Cell Carboxypeptidase A3 Involvement in the Pathogenesis of COVID-19","authors":"A. Budnevskiy, S. N. Avdeev, E. S. Ovsyannikov, N. Alekseeva, V. V. Shishkina, I. Savushkina, I. M. Perveeva, V. R. Drobysheva","doi":"10.58838/2075-1230-2024-102-1-26-33","DOIUrl":"https://doi.org/10.58838/2075-1230-2024-102-1-26-33","url":null,"abstract":"The objective: to determine the involvement of lung mast cell carboxypeptidase A3 (SPA3) in the pathogenesis of COVID-19. Subjects and Methods. Samples of autopsy specimens from the lungs of patients who died of severe COVID-19 and patients who died of external causes were examined. On day 2 after the patient's death, the autopsy was performed and autopsy specimens were collected. Histological samples were prepared to analyze the degranulation activity of CPA3-positive mast cells (MCs). Correlations between protease profile and clinical and laboratory parameters were analyzed.Results. In the patients died of COVID-19, the total numbers of CPA3-positive MCs, CPA3-positive MCs with signs of degranulation, and coadjacent CPA3-positive MCs (two CPA3-positive MCs sharing a common cytoplasm) were statistically significantly higher versus the patients from Control Group. Positive correlations were established between the total number of CPA3-positive MCs and CPA3-positive MCs with signs of degranulation with blood hemoglobin level (r = 0.491; p = 0.008; r = 0.521; p = 0.004), between the total number of CPA3-positive MCs degranulating CPA3-positive MCs and adjacent CPA3-positive MCs with total blood protein (r = 0.431, p = 0.020; r = 0.449, p = 0.015; r = 0.456, p = 0.013), and between CPA3-positive MCs with signs of degranulation and total number of CPA3-positive MCs with aPTT level (r = 0.428; p = 0.021; r = 0.374; p = 0.045). Negative correlations were established between the total number of CPA3-positive MCs and the level of INR (r = 0.812; p = 0.050), separately lying CPA3-positive MCs with the number of monocytes (r = 0.384; p = 0.044), jointly adjacent CPA3-positive Mcs with blood eosinophils (r = 0.420, p = 0.023).","PeriodicalId":37828,"journal":{"name":"Tuberculosis and Lung Diseases","volume":"9 21","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140226296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-20DOI: 10.58838/2075-1230-2024-102-1-66-71
T. I. Kalenchits, S. Kabak, I. V. Korenevskaya
The article describes a clinical case of a 62-year-old patient infected with SARS-CoV-2, in whom, 15 days after the onset of symptoms of COVID-19 with lung damage, chest computed tomography with contrast revealed concurrent subtotal obstruction of the pulmonary artery trunk and defects of its branches filling due to blood clots formed in situ. Against the background of anticoagulant therapy for 13 days, blood clots resolved in both central and peripheral parts of the lung venous bed.
{"title":"Subtotal Thrombosis of the Left Pulmonary Artery Trunk as a Complication of COVID-19: a Clinical Case","authors":"T. I. Kalenchits, S. Kabak, I. V. Korenevskaya","doi":"10.58838/2075-1230-2024-102-1-66-71","DOIUrl":"https://doi.org/10.58838/2075-1230-2024-102-1-66-71","url":null,"abstract":"The article describes a clinical case of a 62-year-old patient infected with SARS-CoV-2, in whom, 15 days after the onset of symptoms of COVID-19 with lung damage, chest computed tomography with contrast revealed concurrent subtotal obstruction of the pulmonary artery trunk and defects of its branches filling due to blood clots formed in situ. Against the background of anticoagulant therapy for 13 days, blood clots resolved in both central and peripheral parts of the lung venous bed.","PeriodicalId":37828,"journal":{"name":"Tuberculosis and Lung Diseases","volume":"18 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140225480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-20DOI: 10.58838/2075-1230-2024-102-1-72-81
G. Mozhokina, A. G. Samoylova, A. Abramchenko, M. I. Romanova, I. A. Vasilyeva
The review analyzes of 69 publications and discusses treatment of drug-resistant tuberculosis from the standpoint of the influence on immune mechanisms that limit progression of inflammation and damage to lung tissue. Interferon-gamma is the most significant cytokine in tuberculosis infection pathogenesis. The article describes genotypic and phenotypic features of interferon-gamma production in various clinical forms of pulmonary tuberculosis. It presents the data supporting the therapeutic use of recombinant interferon-gamma and results of its clinical use as adjuvant treatment additionally to chemotherapy. It demonstrates the prospects for immunotherapy with Ingaron, the drug manufactured in Russia, for patients with multiple drug-resistant pulmonary tuberculosis.
{"title":"Strategy of the Host-Directed Therapy for Tuberculosis: the Importance of Interferon-Gamma in the Pathogenesis and Therapy of Tuberculosis Infection","authors":"G. Mozhokina, A. G. Samoylova, A. Abramchenko, M. I. Romanova, I. A. Vasilyeva","doi":"10.58838/2075-1230-2024-102-1-72-81","DOIUrl":"https://doi.org/10.58838/2075-1230-2024-102-1-72-81","url":null,"abstract":"The review analyzes of 69 publications and discusses treatment of drug-resistant tuberculosis from the standpoint of the influence on immune mechanisms that limit progression of inflammation and damage to lung tissue. Interferon-gamma is the most significant cytokine in tuberculosis infection pathogenesis. The article describes genotypic and phenotypic features of interferon-gamma production in various clinical forms of pulmonary tuberculosis. It presents the data supporting the therapeutic use of recombinant interferon-gamma and results of its clinical use as adjuvant treatment additionally to chemotherapy. It demonstrates the prospects for immunotherapy with Ingaron, the drug manufactured in Russia, for patients with multiple drug-resistant pulmonary tuberculosis.","PeriodicalId":37828,"journal":{"name":"Tuberculosis and Lung Diseases","volume":"7 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140226318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-20DOI: 10.58838/2075-1230-2024-102-1-59-65
I. D. Lagkueva, O. P. Bliznyukov, N. Chernichenko, M. M. Dzhigkaeva, Y. Murzin
The article presents a rare case of verified pulmonary nodular lymphoid hyperplasia (PNLH) in a 49-year-old man with history of chemotherapy and radiation therapy for stage 3B Hodgkin lymphoma with metastases in peripheral lymph nodes and the spleen. It describes computed tomographic semiotics of PNLH and the histological signs of the specimens collected during surgical treatment.
{"title":"Difficulties in Diagnosing Pulmonary Nodular Lymphoid Hyperplasia","authors":"I. D. Lagkueva, O. P. Bliznyukov, N. Chernichenko, M. M. Dzhigkaeva, Y. Murzin","doi":"10.58838/2075-1230-2024-102-1-59-65","DOIUrl":"https://doi.org/10.58838/2075-1230-2024-102-1-59-65","url":null,"abstract":"The article presents a rare case of verified pulmonary nodular lymphoid hyperplasia (PNLH) in a 49-year-old man with history of chemotherapy and radiation therapy for stage 3B Hodgkin lymphoma with metastases in peripheral lymph nodes and the spleen. It describes computed tomographic semiotics of PNLH and the histological signs of the specimens collected during surgical treatment.","PeriodicalId":37828,"journal":{"name":"Tuberculosis and Lung Diseases","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140224238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-20DOI: 10.58838/2075-1230-2024-102-1-52-58
E. Beloborodova, V. N. Zimina, E. Kulabukhova, Т. A. Kuznetsova, O. V. Fesenko
The objective: to study the regional prevalence of mycobacteriosis and the types of non-tuberculous mycobacteria causing mycobacteriosis in Mari El Republic and Vladimir Region, to conduct a comparative clinical and radiological analysis of mycobacteriosis and tuberculosis.Subjects and Methods. Cultures of non-tuberculous mycobacteria available in the bank of the bacteriological laboratory of two regions were analyzed: 182 cultures in the Republic of Mari El and 44 cultures in Vladimir Region. Medical records and X-ray archives of patients who were found to be positive for non-tuberculous mycobacteria were retrospectively studied.Results. The incidence of mycobacteriosis in Vladimir Region and Mari El Republic made 1.5 and 4.3 cases per 100,000 population, respectively. Cultures of non-tuberculous mycobacteria that caused mycobacteriosis belonged to diverse species, and M.avium-complex was the most common (76% of cases). There were no statistically significant differences in the location and extent of lesions in patients with mycobacteriosis and tuberculosis (p > 0.05). The frequency of positive results of Mantoux test with 2TU was comparable Positive results of TRA test were found significantly more often among patients with tuberculosis versus patients with mycobacteriosis (15/19 (78.9%) and 9/24 (37.5%), respectively; p < 0.05). However, this is insufficient for differential diagnosis of these diseases.
{"title":"Comparative Characteristics of Tuberculosis and Mycobacteriosis in Two Regions of the Russian Federation: Mari El Republic and Vladimir Region","authors":"E. Beloborodova, V. N. Zimina, E. Kulabukhova, Т. A. Kuznetsova, O. V. Fesenko","doi":"10.58838/2075-1230-2024-102-1-52-58","DOIUrl":"https://doi.org/10.58838/2075-1230-2024-102-1-52-58","url":null,"abstract":"The objective: to study the regional prevalence of mycobacteriosis and the types of non-tuberculous mycobacteria causing mycobacteriosis in Mari El Republic and Vladimir Region, to conduct a comparative clinical and radiological analysis of mycobacteriosis and tuberculosis.Subjects and Methods. Cultures of non-tuberculous mycobacteria available in the bank of the bacteriological laboratory of two regions were analyzed: 182 cultures in the Republic of Mari El and 44 cultures in Vladimir Region. Medical records and X-ray archives of patients who were found to be positive for non-tuberculous mycobacteria were retrospectively studied.Results. The incidence of mycobacteriosis in Vladimir Region and Mari El Republic made 1.5 and 4.3 cases per 100,000 population, respectively. Cultures of non-tuberculous mycobacteria that caused mycobacteriosis belonged to diverse species, and M.avium-complex was the most common (76% of cases). There were no statistically significant differences in the location and extent of lesions in patients with mycobacteriosis and tuberculosis (p > 0.05). The frequency of positive results of Mantoux test with 2TU was comparable Positive results of TRA test were found significantly more often among patients with tuberculosis versus patients with mycobacteriosis (15/19 (78.9%) and 9/24 (37.5%), respectively; p < 0.05). However, this is insufficient for differential diagnosis of these diseases.","PeriodicalId":37828,"journal":{"name":"Tuberculosis and Lung Diseases","volume":"9 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140227289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-20DOI: 10.58838/2075-1230-2024-102-1-40-45
P. Yablonskiy, B. Vishnevskiy, N. S. Solovyova, V. B. Galkin
The objective: to assess changes in the data on drug resistance of M. tuberculosis for 2015-2021 and compare it with data for 2012-2014.Subjects and Methods. Using continuous sampling, the frequency of drug resistance of Mycobacterium tuberculosis (MTB DR) was studied in isolates from 151 pulmonary tuberculosis (PTB) patients and isolates from 805 extrapulmonary tuberculosis (EPTB) patients, who were treated at the clinic of St. Petersburg Research Institute of Phthisiopulmonology in 2015-2021. The results were compared with similar data for 2012-2014 which was published in 2016.Results. In 2015-2021 versus 2012-2014, the overall frequency of MTB DR decreased by 4.2% in pulmonary tuberculosis patients (from 90.1 to 85.9%) and by 2.9% in extrapulmonary tuberculosis patients (from 80.2 to 77.4%). The structure of MTB DR in pulmonary tuberculosis changed insignificantly, the frequency of MDR decreased from 42.5 to 36.5%, and XDR (as per the definitions before 2022) remained the same – 39.5%. In extrapulmonary tuberculosis, the structure of MTB DR deteriorated due to lower frequency of MDR (from 66.3 to 48.3%) and higher frequency of XDR (from 3.2 to 19.0%, p<0.01).
{"title":"Frequency and Structure of Drug Resistance of M. tuberculosis in Pulmonary and Extrapulmonary Tuberculosis","authors":"P. Yablonskiy, B. Vishnevskiy, N. S. Solovyova, V. B. Galkin","doi":"10.58838/2075-1230-2024-102-1-40-45","DOIUrl":"https://doi.org/10.58838/2075-1230-2024-102-1-40-45","url":null,"abstract":"The objective: to assess changes in the data on drug resistance of M. tuberculosis for 2015-2021 and compare it with data for 2012-2014.Subjects and Methods. Using continuous sampling, the frequency of drug resistance of Mycobacterium tuberculosis (MTB DR) was studied in isolates from 151 pulmonary tuberculosis (PTB) patients and isolates from 805 extrapulmonary tuberculosis (EPTB) patients, who were treated at the clinic of St. Petersburg Research Institute of Phthisiopulmonology in 2015-2021. The results were compared with similar data for 2012-2014 which was published in 2016.Results. In 2015-2021 versus 2012-2014, the overall frequency of MTB DR decreased by 4.2% in pulmonary tuberculosis patients (from 90.1 to 85.9%) and by 2.9% in extrapulmonary tuberculosis patients (from 80.2 to 77.4%). The structure of MTB DR in pulmonary tuberculosis changed insignificantly, the frequency of MDR decreased from 42.5 to 36.5%, and XDR (as per the definitions before 2022) remained the same – 39.5%. In extrapulmonary tuberculosis, the structure of MTB DR deteriorated due to lower frequency of MDR (from 66.3 to 48.3%) and higher frequency of XDR (from 3.2 to 19.0%, p<0.01).","PeriodicalId":37828,"journal":{"name":"Tuberculosis and Lung Diseases","volume":"23 27","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140226249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-20DOI: 10.58838/2075-1230-2024-102-1-82-86
A. V. Takhtamysheva
This review analyzes 33 publications on the effectiveness of inhaled antibiotics in patients with cystic fibrosis and evaluates their effect on bacterial resistance.
本综述分析了 33 篇关于吸入式抗生素对囊性纤维化患者疗效的文献，并评估了其对细菌耐药性的影响。
{"title":"Treatment with Inhaled Antibiotics as One of the Measures to Combat Bacterial Resistance (Cystic Fibrosis is Used as an Example)","authors":"A. V. Takhtamysheva","doi":"10.58838/2075-1230-2024-102-1-82-86","DOIUrl":"https://doi.org/10.58838/2075-1230-2024-102-1-82-86","url":null,"abstract":"This review analyzes 33 publications on the effectiveness of inhaled antibiotics in patients with cystic fibrosis and evaluates their effect on bacterial resistance.","PeriodicalId":37828,"journal":{"name":"Tuberculosis and Lung Diseases","volume":"54 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140224301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-20DOI: 10.58838/2075-1230-2024-102-1-46-51
L. T. Eralieva, K. S. Serikbaeva, A. Rakisheva, Z. S. Bekbenbetova, O. G. Prikhodchenko
The objective: to improve organizational measures for detection and diagnosing of tuberculous infection and tuberculosis in adolescents in the Republic of Kazakhstan.Subjects and Methods. Screening was conducted among 27,648 adolescents aged 15-17 years from regions of the Republic of Kazakhstan with a high burden of tuberculosis. It was planned to use TRA tests and fluorography in parallel, while local doctors, district and school nurses, and nurses in vaccination rooms were preliminary trained by pediatric phthisiologists to perform the test, evaluate its results and monitor manifestations of adverse events (AEs) caused by TRA test.Results. 27,648 adolescents (aged 15-17 years) were given TRA test. No adverse events were observed during TRA skin test. Latent tuberculous infection was diagnosed in 320 (1.2%) adolescents. During further examination, 10 patients were diagnosed with drug susceptible pulmonary tuberculosis with no bacillary excretion. Based on the study results, to detect LTBI and tuberculosis in adolescents, in addition to fluorography examination, it is necessary to use TRA skin test with in the groups facing a high risk of tuberculosis.
目的：改善哈萨克斯坦共和国青少年结核感染和结核病检测与诊断的组织措施。对哈萨克斯坦共和国结核病高发地区的 27 648 名 15-17 岁青少年进行了筛查。当地医生、地区和学校护士以及疫苗接种室护士接受了儿科噬菌体学专家的初步培训，以进行检测、评估检测结果并监测由 TRA 检测引起的不良事件（AEs）表现。27648名青少年（15-17岁）接受了TRA测试。在 TRA 皮试过程中未发现任何不良反应。320名青少年（1.2%）被诊断为潜伏结核感染。在进一步检查中，有 10 名患者被确诊为对药物敏感的肺结核，且没有排出结核杆菌。根据研究结果，要检测青少年的迟发性肺结核和肺结核，除了荧光造影检查外，还有必要在肺结核高危人群中使用 TRA 皮试。
{"title":"Improvement of Organizational Measures for Detection and Diagnosing of Tuberculous Infection and Tuberculosis in Adolescents in the Republic of Kazakhstan","authors":"L. T. Eralieva, K. S. Serikbaeva, A. Rakisheva, Z. S. Bekbenbetova, O. G. Prikhodchenko","doi":"10.58838/2075-1230-2024-102-1-46-51","DOIUrl":"https://doi.org/10.58838/2075-1230-2024-102-1-46-51","url":null,"abstract":"The objective: to improve organizational measures for detection and diagnosing of tuberculous infection and tuberculosis in adolescents in the Republic of Kazakhstan.Subjects and Methods. Screening was conducted among 27,648 adolescents aged 15-17 years from regions of the Republic of Kazakhstan with a high burden of tuberculosis. It was planned to use TRA tests and fluorography in parallel, while local doctors, district and school nurses, and nurses in vaccination rooms were preliminary trained by pediatric phthisiologists to perform the test, evaluate its results and monitor manifestations of adverse events (AEs) caused by TRA test.Results. 27,648 adolescents (aged 15-17 years) were given TRA test. No adverse events were observed during TRA skin test. Latent tuberculous infection was diagnosed in 320 (1.2%) adolescents. During further examination, 10 patients were diagnosed with drug susceptible pulmonary tuberculosis with no bacillary excretion. Based on the study results, to detect LTBI and tuberculosis in adolescents, in addition to fluorography examination, it is necessary to use TRA skin test with in the groups facing a high risk of tuberculosis.","PeriodicalId":37828,"journal":{"name":"Tuberculosis and Lung Diseases","volume":"23 39","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140226054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-19DOI: 10.58838/2075-1230-2024-102-1-6-11
E. Veselova, G. Kaminskiy, K. A. Kocharyan, A. B. Peregudova, O. V. Lovacheva, A. G. Samoylova
The course of HIV infection depends on the degree of HIV suppression during ART.The objective: to evaluate feasibility of using three factors: viral load (VL), HIV reservoir and CD8 T cells before ART initiation to estimate future levels of “residual” viremia and develop a predictive model.Subjects and Methods. 74 naive patients with HIV infection were enrolled in the study. The HIV reservoir, VL and CD4, CD8 counts were tested before ART initiation and then every 6 months. The patients were followed up for 12 months. Discriminant analysis was used.Results. After 12 months of ART, 69/74 (93.2%) patients had undetectable VL including 14 patients with residual viremia (RV) and 55 in whom no virus was detected. The probability of persisting RV after 12 months of ART was assessed first by one factor – VL prior to ART, after that by three factors – VL, HIV reservoir (HIV DNA), CD8 count prior to ART. A predictive model formula was generated using those factors: D = -5.288-0.001 CD8+1.342VL+0.08 HIV DNA. With discriminant function D>0.065, the patient has a high probability of RV after 12 months of ART; with D ≤0.065, the probability of RV is low. This prognosis should be taken into account when choosing an ART regimen ensuring its maximum optimization.
{"title":"A Predictive Model of the HIV Infection Course","authors":"E. Veselova, G. Kaminskiy, K. A. Kocharyan, A. B. Peregudova, O. V. Lovacheva, A. G. Samoylova","doi":"10.58838/2075-1230-2024-102-1-6-11","DOIUrl":"https://doi.org/10.58838/2075-1230-2024-102-1-6-11","url":null,"abstract":"The course of HIV infection depends on the degree of HIV suppression during ART.The objective: to evaluate feasibility of using three factors: viral load (VL), HIV reservoir and CD8 T cells before ART initiation to estimate future levels of “residual” viremia and develop a predictive model.Subjects and Methods. 74 naive patients with HIV infection were enrolled in the study. The HIV reservoir, VL and CD4, CD8 counts were tested before ART initiation and then every 6 months. The patients were followed up for 12 months. Discriminant analysis was used.Results. After 12 months of ART, 69/74 (93.2%) patients had undetectable VL including 14 patients with residual viremia (RV) and 55 in whom no virus was detected. The probability of persisting RV after 12 months of ART was assessed first by one factor – VL prior to ART, after that by three factors – VL, HIV reservoir (HIV DNA), CD8 count prior to ART. A predictive model formula was generated using those factors: D = -5.288-0.001 CD8+1.342VL+0.08 HIV DNA. With discriminant function D>0.065, the patient has a high probability of RV after 12 months of ART; with D ≤0.065, the probability of RV is low. This prognosis should be taken into account when choosing an ART regimen ensuring its maximum optimization.","PeriodicalId":37828,"journal":{"name":"Tuberculosis and Lung Diseases","volume":"60 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140230531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-19DOI: 10.58838/2075-1230-2024-102-1-12-19
D. Plotkin, A. I. Titomer, K. Lobastov, M. N. Reshetnikov, M. V. Sinitsyn, R. V. Maltsev, N. Demchenkov, A. M. Abdurakhmanov, S. Sterlikov, E. M. Bogorodskaya
The objective: to evaluate VTEC in new tuberculosis patients and relapses, to determine main factors influencing its development (according to data of the patients admitted to Moscow tuberculosis hospitals)Subjects and Methods. Based on the data of epidemiological tuberculosis monitoring system of Moscow, treatment outcomes of 4609 tuberculosis patients admitted to tuberculosis hospitals from 2020 to 2022 were retrospectively analyzed. The incidence of VTEC was estimated.Results. Totally 214/4609 cases of VTEC were identified (4.6%; 95% CI 4.1-5.3%), among which the incidence of DVT made 3.5% (95% CI 3.0-4.1%), SVP 1.5% (95% CI 1.2-1.9%), and PATE 0.6% (95% CI 0.4-0.8%). The most significant risk factors of thrombotic complications in tuberculosis patients were identified, those factors included HIV infection (RR 3.8; 95% CI 2.7-4.5) and fibrous cavernous form of pulmonary tuberculosis (RR 9.1; 95% CI 4.7-17.6). The overall prevalence of VTEC in tuberculosis hospitals was 3 or more times higher than in general clinics (according to the published data).Conclusion. The data obtained indicate that patients hospitalized for pulmonary tuberculosis face a high risk of VTEC development that requires prediction and prevention.
目的：评估新肺结核患者和复发患者的VTEC，确定影响其发展的主要因素（根据莫斯科结核病医院收治患者的数据）。根据莫斯科结核病流行病学监测系统的数据，对2020年至2022年结核病医院收治的4609名结核病患者的治疗结果进行了回顾性分析。结果。共发现 214/4609 例 VTEC（4.6%；95% CI 4.1-5.3%），其中深静脉血栓的发生率为 3.5%（95% CI 3.0-4.1%），SVP 为 1.5%（95% CI 1.2-1.9%），PATE 为 0.6%（95% CI 0.4-0.8%）。研究发现了肺结核患者血栓并发症最重要的风险因素，包括艾滋病毒感染（RR 3.8；95% CI 2.7-4.5）和纤维空洞型肺结核（RR 9.1；95% CI 4.7-17.6）。结核病医院的 VTEC 总发病率是普通诊所的 3 倍或以上（根据已公布的数据）。所获得的数据表明，因肺结核住院的患者面临着发生 VTEC 的高风险，需要进行预测和预防。
{"title":"Prevalence of Nosocomial Venous Thromboembolic Complications in New Tuberculosis Patients and Relapses: Data from the Moscow City Registry (A Multicenter Study)","authors":"D. Plotkin, A. I. Titomer, K. Lobastov, M. N. Reshetnikov, M. V. Sinitsyn, R. V. Maltsev, N. Demchenkov, A. M. Abdurakhmanov, S. Sterlikov, E. M. Bogorodskaya","doi":"10.58838/2075-1230-2024-102-1-12-19","DOIUrl":"https://doi.org/10.58838/2075-1230-2024-102-1-12-19","url":null,"abstract":"The objective: to evaluate VTEC in new tuberculosis patients and relapses, to determine main factors influencing its development (according to data of the patients admitted to Moscow tuberculosis hospitals)Subjects and Methods. Based on the data of epidemiological tuberculosis monitoring system of Moscow, treatment outcomes of 4609 tuberculosis patients admitted to tuberculosis hospitals from 2020 to 2022 were retrospectively analyzed. The incidence of VTEC was estimated.Results. Totally 214/4609 cases of VTEC were identified (4.6%; 95% CI 4.1-5.3%), among which the incidence of DVT made 3.5% (95% CI 3.0-4.1%), SVP 1.5% (95% CI 1.2-1.9%), and PATE 0.6% (95% CI 0.4-0.8%). The most significant risk factors of thrombotic complications in tuberculosis patients were identified, those factors included HIV infection (RR 3.8; 95% CI 2.7-4.5) and fibrous cavernous form of pulmonary tuberculosis (RR 9.1; 95% CI 4.7-17.6). The overall prevalence of VTEC in tuberculosis hospitals was 3 or more times higher than in general clinics (according to the published data).Conclusion. The data obtained indicate that patients hospitalized for pulmonary tuberculosis face a high risk of VTEC development that requires prediction and prevention.","PeriodicalId":37828,"journal":{"name":"Tuberculosis and Lung Diseases","volume":"14 3‐4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140230571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：